Dr. Felix Karim, Ph.D. serves as Executive Vice President of Business Development at Blade Therapeutics, Inc. Dr. Karim served as Vice President of Corporate & Business Development at Compugen Ltd. since March 02, 2015 until July 9, 2016. Dr. Karim has significant experience in the biopharmaceutical industry and has held various executive roles in business development and R&D management. Prior to Compugen, he served as Head of External R&D (licensing) for the San Francisco region at Amgen. Before Amgen, Dr. Karim served as a Vice President of Business Development at KAI Pharmaceuticals, where he led business development and transaction activities, including the sale of KAI Pharmaceuticals to Amgen. Dr. Karim has also held various positions at Exelixis and Celera Genomics, leading multidisciplinary teams across a broad range of activities in R&D and program development and has played an integral role in business development efforts that resulted in significant pharma partnerships. Dr. Karim holds a bachelor's degree in biochemistry from the University of California, Berkeley and a PhD from the Department of Human Genetics at the University of Utah Medical School. Dr. Felix Karim, Ph.D. serves as Executive Vice President of Business Development at Blade Therapeutics, Inc. Dr. Karim served as Vice President of Corporate & Business Development at Compugen Ltd. since March 02, 2015 until July 9, 2016. Dr. Karim has significant experience in the biopharmaceutical industry and has held various executive roles in business development and R&D management. Prior to Compugen, he served as Head of External R&D (licensing) for the San Francisco region at Amgen. Before Amgen, Dr. Karim served as a Vice President of Business Development at KAI Pharmaceuticals, where he led business development and transaction activities, including the sale of KAI Pharmaceuticals to Amgen. Dr. Karim has also held various positions at Exelixis and Celera Genomics, leading multidisciplinary teams across a broad range of activities in R&D and program development and has played an integral role in business development efforts that resulted in significant pharma partnerships. Dr. Karim holds a bachelor's degree in biochemistry from the University of California, Berkeley and a PhD from the Department of Human Genetics at the University of Utah Medical School.

Medical & Surgical Pathology